Teladoc Health (NYSE:TDOC) Price Target Lowered to $6.00 at TD Cowen

Teladoc Health (NYSE:TDOC) had its price target cut by equities researchers at TD Cowen from $8.00 to $6.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the health services provider’s stock. TD Cowen’s target price suggests a potential upside of 12.89% from the company’s previous close.

TDOC has been the topic of a number of other reports. Citigroup lowered their price objective on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Friday, January 9th. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 target price (down from $12.00) on shares of Teladoc Health in a report on Thursday. Barclays initiated coverage on shares of Teladoc Health in a research note on Tuesday, December 9th. They set an “equal weight” rating and a $8.50 price target on the stock. BMO Capital Markets assumed coverage on shares of Teladoc Health in a research report on Thursday, November 13th. They issued a “market perform” rating and a $8.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $8.11.

Teladoc Health Stock Performance

TDOC stock traded up $0.67 during trading on Thursday, hitting $5.32. The company had a trading volume of 14,644,582 shares, compared to its average volume of 6,787,662. The firm has a 50-day moving average price of $6.06 and a 200-day moving average price of $7.22. The company has a quick ratio of 2.60, a current ratio of 2.70 and a debt-to-equity ratio of 0.71. The firm has a market cap of $943.25 million, a PE ratio of -4.15 and a beta of 2.12. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $10.02.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. Teladoc Health had a negative return on equity of 10.59% and a negative net margin of 8.84%.The firm’s revenue for the quarter was up .3% on a year-over-year basis. During the same period last year, the firm earned ($0.28) EPS. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. On average, analysts expect that Teladoc Health will post -1.16 earnings per share for the current year.

Insider Activity at Teladoc Health

In other news, CEO Charles Divita III sold 17,138 shares of Teladoc Health stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $7.63, for a total transaction of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares in the company, valued at approximately $1,533,904.68. This trade represents a 7.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Fernando M. Rodrigues sold 4,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $7.48, for a total value of $31,483.32. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 33,288 shares of company stock worth $251,684 over the last three months. 0.58% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Teladoc Health by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock worth $1,542,000 after purchasing an additional 5,235 shares in the last quarter. NewEdge Advisors LLC boosted its position in shares of Teladoc Health by 1,278.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after buying an additional 10,485 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after acquiring an additional 24,124 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Teladoc Health in the 1st quarter valued at about $615,000. Finally, AlphaQuest LLC increased its holdings in Teladoc Health by 768.2% during the 2nd quarter. AlphaQuest LLC now owns 32,341 shares of the health services provider’s stock valued at $282,000 after acquiring an additional 28,616 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 results beat expectations — Teladoc reported revenue of $642.3M (above $635.3M consensus) and EPS of ($0.14), topping estimates. The beat reduces near‑term earnings uncertainty and provides proof of stabilization after prior losses. Q4 sales surprise
• Positive Sentiment: Conference call highlighted growth in Integrated Care and strategic repositioning of BetterHelp — management emphasized areas of improving unit economics and product focus that could drive margin recovery over time. Investors often reward visible operational progress even when near‑term guidance is cautious. Earnings call highlights
• Neutral Sentiment: Deeper metric readouts available — analysts and outlets (e.g., Zacks) are parsing subscriber, utilization and margin metrics to assess sustainability of the beat; these details will influence revisions to models but don’t yet change the headline picture. Zacks analysis
• Negative Sentiment: Forward guidance disappointed — Q1 2026 EPS guidance of -0.450 to -0.350 and FY 2026 EPS of -1.100 to -0.700 both sit below consensus; Q1 revenue guidance ($598M–$620M) is also below Street estimates. This increases near‑term downside risk and keeps profitability recovery uncertain. Guidance details
• Negative Sentiment: Analysts cut price targets — Wells Fargo and Stifel reduced targets from $8 to $6 and kept neutral/hold stances, signaling tempered expectations for upside and contributing to mixed sell‑side sentiment. Benzinga

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.